Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Camrelizumab, an mAb against programmed cell death protein 1 (PD-1), plus nab-paclitaxel exhibited promising antitumor activity in refractory metastatic immunomodulatory triple-negative breast cancer (TNBC). Famitinib is a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit. We aimed to ass...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research 2022-07, Vol.28 (13), p.2807-2817
Hauptverfasser:	Chen, Li, Jiang, Yi-Zhou, Wu, Song-Yang, Wu, Jiong, Di, Gen-Hong, Liu, Guang-Yu, Yu, Ke-Da, Fan, Lei, Li, Jun-Jie, Hou, Yi-Feng, Hu, Zhen, Chen, Can-Ming, Huang, Xiao-Yan, Cao, A-Yong, Hu, Xin, Zhao, Shen, Ma, Xiao-Yan, Xu, Ying, Sun, Xiang-Jie, Chai, Wen-Jun, Guo, Xiaomao, Chen, Xizi, Xu, Yanhui, Zhu, Xiao-Yu, Zou, Jian-Jun, Yang, Wen-Tao, Wang, Zhong-Hua, Shao, Zhi-Ming
Format:	Artikel
Sprache:	eng
Schlagworte:	Albumins - administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects B7-H1 Antigen Clinical Trials: Immunotherapy Humans Indoles Paclitaxel - administration & dosage Pyrroles Triple Negative Breast Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!